Dr. Jacob Rosenstein, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 800 W Arbrook Blvd, Suite 150, Arlington, TX 76015 Phone: 817-467-5551 Fax: 817-465-2775 |
Sabatino Bianco, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1001 N Waldrop Dr, Suite 403, Arlington, TX 76012 Phone: 817-701-4253 Fax: 817-701-4258 |
Gaddum Duemani Reddy, M.D., PH.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 515 W Mayfield Rd Ste 407, Arlington, TX 76014 Phone: 713-392-7289 |
Dr. Frederick D. Todd Ii, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 W Arbrook Blvd, 250, Arlington, TX 76015 Phone: 817-465-7764 Fax: 817-465-8117 |
Clay Madison Elswick, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 515 W Mayfield Rd Ste 407, Arlington, TX 76014 Phone: 682-219-0357 Fax: 817-419-2943 |
Dr. Jeffrey W. Heitkamp, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 811 W Interstate 20 Unit G10, Arlington, TX 76017 Phone: 817-274-4593 Fax: 817-274-4098 |
News Archive
A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, "Enhanced antibody half-life improves in vivo activity" demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.
Evidence in a study led by researchers at the University of British Columbia along with University of Alabama at Birmingham School of Public Health Associate Professor Peter S. Hendricks, Ph.D., suggests hallucinogens such as psilocybin or LSD may have therapeutic potential for reducing intimate partner violence, or IPV.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
A geocoding approach - linking routinely collected public health data to neighborhood socioeconomic factors - shows consistently higher rates of COVID-19 illness and death among people living in more-disadvantaged communities, reports a study in the November/December Journal of Public Health Management and Practice.
› Verified 9 days ago